Amgen’s Stelara Biosimilar Produces Positive Phase III Results

Firm’s ABP 654 Ustekinumab Candidate Is Also Being Lined Up For Interchangeability

Amgen offices at Cambridge Science Park
Amgen has announced progress on its ustekinumab candidate • Source: Alamy

More from Biosimilars

More from Products